LONDON Dec 6 British drugmaker Shire,
whose shares have performed strongly this year, reported mixed
results with a key new drug for dry eye disease on Friday,
leaving the future of the product unclear.
Lifitegrast did reduce patient-reported symptoms of dryness
in a late-stage trial - the first drug to do so in a Phase III
setting - but it missed a second target that measured signs of
the disease based on corneal staining.
The findings from the latest trial contrast with those of an
earlier Phase III one that found an improvement in disease
signs, but not in symptoms.
Lifitegrast - a potential competitor for Allergan's
Restasis - is viewed as a key new product for Shire as it seeks
to diversify its product line-up.
Shire Chief Executive Flemming Ornskov said the company
would now examine the totality of the data across the clinical
trials and discuss the future of the lifitegrast programme with
Shire obtained lifitegrast after buying U.S. biotech firm
SARcode Bioscience for an initial $160 million in March, marking
a sizeable bet on the ophthalmology space by Britain's third
Shire has been hoping to launch lifitegrast in the United
States as early as 2016.